Skip to Content
Global News Select

AC Immunity Shares Soar on Exclusive License Deal with Takeda

By Dean Seal


Shares of AC Immunity surged after the company signed announced an agreement with Takeda Pharmaceutical for an exclusive option to license its active immunotherapy for Alzheimer's disease.

The stock was up 64% at $3.80 in premarket trading. Shares had fallen by more than 50% year-to-date when the market closed Friday.

The biopharmaceutical company said Monday morning that Takeda will receive an exclusive option to license global rights to ACT-24.060, AC Immune's active immunotherapy designed to delay or slow Alzheimer's disease progression.

AC Immune is set to receive an upfront payment of $100 million upon closing and be eligible for additional milestone payments of up to $2.1 billion.


Write to Dean Seal at


(END) Dow Jones Newswires

May 13, 2024 07:26 ET (11:26 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Market Updates

Sponsor Center